New cocktail of chemo and immunotherapy aims to fight advanced ovarian cancer
NCT ID NCT05952453
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pembrolizumab) to help keep the cancer from coming back. The study will track how long the cancer stays under control, with 20 participants expected to enroll.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carboplatin, paclitaxel, pembrolizumab, olaparib
What this could lead to
If successful, this could improve how long advanced ovarian cancer stays under control after initial treatment.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination of drugs may cause side effects, and the benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
O'Neal Comprehensive Cancer Center at UAB
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Contact